Drinabant

Drinabant
Clinical data
ATC code
  • None
Identifiers
  • (±)-N-{1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl}-N-(3,5-difluorophenyl)methanesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H20Cl2F2N2O2S
Molar mass497.38 g·mol−1
3D model (JSmol)
  • Fc1cc(cc(F)c1)N(C4CN(C(c2ccc(Cl)cc2)c3ccc(Cl)cc3)C4)S(=O)(=O)C
  • InChI=1S/C23H20Cl2F2N2O2S/c1-32(30,31)29(21-11-19(26)10-20(27)12-21)22-13-28(14-22)23(15-2-6-17(24)7-3-15)16-4-8-18(25)9-5-16/h2-12,22-23H,13-14H2,1H3
  • Key:IQQBRKLVEALROM-UHFFFAOYSA-N

Drinabant (INN; AVE-1625) is a drug that acts as a selective CB1 receptor antagonist, which was under investigation varyingly by Sanofi-Aventis as a treatment for obesity, schizophrenia, Alzheimer's disease, Parkinson's disease, and nicotine dependence.[1][2][3] Though initially studied as a potential treatment for a variety of different medical conditions, Sanofi-Aventis eventually narrowed down the therapeutic indications of the compound to just appetite suppression. Drinabant reached phase IIb clinical trials for this purpose in the treatment of obesity but was shortly thereafter discontinued,[4] likely due to the observation of severe psychiatric side effects including anxiety, depression, and thoughts of suicide in patients treated with the now-withdrawn CB1R antagonist rimonabant.[5]

In late 2018, the drug was licensed by Opiant Pharmaceuticals, which intends to develop it for the treatment of acute cannabinoid overdose (ACO) as an injectable for administration in an emergency department setting. Opiant claims that ACO is most frequently linked to the ingestion of cannabis edibles and/or synthetic cannabinoids that are more potent and less expensive than natural cannabis extracts such as hash oil. Edibles, sold as capsules, brownies, cookies, chocolate bars and gumdrops, may pose particular risks for children, who may consume these by accident. The existence of ACO is heavily debated. In fact, most people who die from cannabinoid ingestion have had chronic life-long heart problems or are involved in accidents from driving while intoxicated.[6]

Rimonabant was another cannabinoid receptor antagonist developed for prescription drug use that triggered severe psychiatric side effects and was withdrawn from the market.

See also

References

  1. ^ Lange JH, Kruse CG (2008). "Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives". Chemical Record. 8 (3): 156–168. doi:10.1002/tcr.20147. PMID 18563799.
  2. ^ Kwon MO, Herrling P (2005). "List of drugs in development for neurodegenerative diseases. Update September 2005". Neuro-Degenerative Diseases. 2 (2): 61–108. doi:10.1159/000089285. PMID 16909049. S2CID 2553974.
  3. ^ Litwack G (14 August 2009). Anandamide. Academic Press. p. 172. ISBN 978-0-12-374782-2. Retrieved 13 May 2012.
  4. ^ Reggio PH (2009). "Toward the design of cannabinoid CB1 receptor inverse agonists and neutral antagonists". Drug Development Research. 70 (8): 585–600. doi:10.1002/ddr.20337. ISSN 0272-4391. S2CID 83478850.
  5. ^ Lee HK, Choi EB, Pak CS (2009). "The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current Topics in Medicinal Chemistry. 9 (6): 482–503. doi:10.2174/156802609788897844. PMID 19689362. Archived from the original on 2013-05-22. Retrieved 2019-07-29.
  6. ^ Suriaga A, Tappen RM, Aston ER, Chiang-Hanisko L, Newman D (May 2023). "Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications". Journal of Nursing Scholarship. 55 (3): 623–636. doi:10.1111/jnu.12817. PMC 11537499. PMID 36250599.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.